John Kuryan, MD
Allergy & Immunology · Willow Grove, PANPI 1528294790
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Sanofi at 33.8% of the total. 2025 is the largest year on record at $6,572, 5.7 times the $1,146 reported in 2019.
Across 285 payments — averaging $63.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- Novartis$6K
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$533
- Blueprint Medicines Corporation$382
- plus $2K from 22 others
What the payments were for
- Consulting fees$9,99755%
- Travel & lodging$3162%
- Food & beverage$7,64542%
- Education$1101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 31 | $6,098 |
| Novartis | 17 | $5,877 |
| AstraZeneca | 62 | $1,671 |
| GSK | 65 | $1,117 |
| Regeneron Healthcare Solutions, Inc. | 17 | $533 |
| Blueprint Medicines Corporation | 5 | $382 |
| Optinose US, Inc. | 10 | $349 |
| Amgen | 4 | $229 |
| Kaleo, Inc. | 14 | $228 |
| Biocryst US Sales Co., LLC | 4 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $219 |
| Genentech USA, Inc. | 12 | $193 |
| Pfizer | 6 | $180 |
| AbbVie | 5 | $165 |
| Dermavant Sciences, Inc. | 1 | $90 |
| Aquestive Therapeutics, Inc. | 1 | $83 |
| Hikma Pharmaceuticals USA | 2 | $67 |
| Grifols USA, LLC | 2 | $59 |
| Alk-abello, Inc | 3 | $51 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Shire North American Group Inc | 2 | $37 |
| Merck | 3 | $36 |
| Covis Pharma GmbH | 1 | $29 |
| Octapharma USA, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Bio Products Laboratory USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,067 in reported general payments places this provider in the 80th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 179 | $196,615 |
| Dupixent PenDupilumab | 25 | $95,525 |
| XolairOmalizumab | 26 | $57,442 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $36,125 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $14,770 |
| Arnuity ElliptaFluticasone Furoate | 24 | $9,649 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 58 | $9,494 |
| Epinephrine | 42 | $7,004 |
| DuleraMometasone/Formoterol | 17 | $6,239 |
| Pulmicort FlexhalerBudesonide | 11 | $4,449 |
| Fluticasone Propionate | 151 | $4,437 |
| Ipratropium Bromide | 93 | $3,760 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $3,690 |
| Desloratadine | 19 | $2,747 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,117 | $242,388249 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $1,671 | $19,21949 claims |
| Hikma Pharmaceuticals USAEpinephrine | $67 | $7,00442 claims |
| MerckDulera | $36 | $6,23917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Willow Grove
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Shailen ShahCollegeville$183K
- Michael PremattaHavertown$168K
- Donald HarperMechanicsburg$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.